NewLeaf Symbiotics Secures Key Patents in Europe and Japan

ST. LOUIS, MO, UNITED STATES - Aug 16, 2016 - NewLeaf Symbiotics announced today that both the European and Japanese Patent Offices will grant patents on the company’s foundational production process. In 2015, the U.S. Patent and Trademark Office granted U.S. Patent No. 9,181,541 broadly covering NewLeaf’s proprietary production technology. The technology disclosed in the patents permits rapid, cost-effective production of large quantities of Pink-Pigmented Facultative Methylotrophs (PPFM), a naturally occurring beneficial bacteria which can improve yield and pest tolerance in treated crops.  

Desmond Jimenez, vice president for product development at NewLeaf said, “The grant of patents in Europe and Japan is significant for the company because we expect production and commercialization of our products to scale throughout the world. We are beginning sales in the U.S. and Canada, and have conducted successful tests in South America. We see real opportunity in Europe and Japan as these markets are hungry for more sustainable agricultural practices and NewLeaf can fill that demand.”

PPFM bacteria live on all plant surfaces and inside plants. They form complex symbiotic relationships with host plants and with other microbes in the environment. PPFMs utilize methanol and other plant waste materials, and produce necessary nutrients that the plant absorbs. Bacterial members of the microbiome are essential to plant health and growth.

Charley Romano, senior patent agent at Thompson Coburn LLP, drafted and prosecuted the patent applications in collaboration with NewLeaf inventor Gregg Bogosian and foreign patent counsel. Romano commented, “I have worked closely with the NewLeaf team for over four years to create a broad patent portfolio that is aligned with their commercial plans. Three key jurisdictions with rigorous patent examination procedures have conferred patent rights for NewLeaf’s first family of production patent applications. We now look forward to securing patent rights for NewLeaf in additional countries in Asia and North and South America.” 

About NewLeaf Symbiotics
NewLeaf Symbiotics is a venture-funded agricultural biologicals company engaged in discovery, development, production, and commercialization of products containing beneficial plant bacteria.  Its 30+member team is based in BRDG Park at the Donald Danforth Plant Science Center in St Louis, Missouri.  Visit NewLeaf Symbiotics at www.newleafsym.com.

About BRDG Park at the Danforth Center
Bio Research & Development Growth (BRDG) Park at the Danforth Plant Science Center helps life science companies bridge research, resources and relationships to achieve commercial success. In addition to providing world-class wet laboratories, office space and a prominent incubator, BRDG Park’s location on the Danforth Center’s campus facilitates access to the intellectual capital of top scientists, as well as to greenhouses, growth chambers, microscopy and proteomics facilities and other vital resources. More information is available at www.BRDG-Park.com